ITT2922
ITT2922
- Catalog: ITT2922
- Gene/Protein: MUC16
- Product Description: Immunotag™ Mucin 16 Polyclonal Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet | 
|
| Target Protein | Mucin 16 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | IF,ELISA |
| Recommended Dilution | Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MUC16. AA range:13311-13360 |
| Specificity | Mucin 16 Polyclonal Antibody detects endogenous levels of Mucin 16 protein. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
| Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Gene Name | MUC16 |
| Accession No. | Q8WXI7 |
| Alternate Names | MUC16; CA125; Mucin-16; MUC-16; Ovarian cancer-related tumor marker CA125; CA-125; Ovarian carcinoma antigen CA125 |
| Description | domain:Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.,function:Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.,induction:Up-regulated in ovarian cancer cells.,miscellaneous:Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.,polymorphism:The number of repeats is highly polymorphic.,PTM:Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.,PTM:Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.,PTM:May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.,PTM:May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.,similarity:Contains 14 LRR (leucine-rich) repeats.,similarity:Contains 2 ANK repeats.,similarity:Contains 56 SEA domains.,subcellular location:May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.,subunit:Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.,tissue specificity:Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas., |
| Protein Expression | Placenta,Trachea,Uterus, |
| Subcellular Localization | extracellular space,Golgi lumen,plasma membrane,integral component of membrane,extrinsic component of membrane,vesicle,extracellular exosome, |
| Protein Function | domain:Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.,function:Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.,induction:Up-regulated in ovarian cancer cells.,miscellaneous:Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.,polymorphism:The number of repeats is highly polymorphic.,PTM:Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.,PTM:Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.,PTM:May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.,PTM:May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.,similarity:Contains 14 LRR (leucine-rich) repeats.,similarity:Contains 2 ANK repeats.,similarity:Contains 56 SEA domains.,subcellular location:May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.,subunit:Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.,tissue specificity:Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|